Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | TLR8 | Q9NR97 | 15/20 | 0.44 |
| ▸ | TLR7 | Q9NYK1 | 13/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17035559 | 0.87 | FLT3 (0.44) | L3MBTL1TLR8TLR7FLT3PDE4B | |
| SCHEMBL23472257 | 0.81 | L3MBTL1 (0.58) | L3MBTL1TLR8TLR7 | |
| SCHEMBL17035546 | 0.81 | TLR8 (0.62) | L3MBTL1TLR8TLR7 | |
| SCHEMBL13195740 | 0.80 | L3MBTL1 (0.57) | L3MBTL1TLR8TLR7 | |
| SCHEMBL20219510 | 0.80 | TLR8 (0.55) | L3MBTL1TLR8TLR7 | |
| SCHEMBL20219632 | 0.79 | L3MBTL1 (0.48) | L3MBTL1TLR8TLR7 | |
| SCHEMBL20219655 | 0.78 | TLR8 (0.50) | L3MBTL1TLR8TLR7 | |
| SCHEMBL17035549 | 0.78 | TLR8 (0.57) | L3MBTL1TLR8TLR7 | |
| SCHEMBL23472442 | 0.77 | TLR8 (0.52) | L3MBTL1TLR8TLR7 | |
| SCHEMBL20219645 | 0.77 | TLR8 (0.51) | L3MBTL1TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9284304-B2 | Substituted pyrimidines as toll-like receptor modulators | JANSSEN SCIENCES IRELAND UC (IE) | 2016-03-15 | — | — | US | disclosed |
| US-20150239872-A1 | ALKYLPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND FURTHER DISEASES | JANSSEN SCIENCES IRELAND UC (IE) | 2015-08-27 | — | — | US | disclosed |
| US-20150239872-A1 | ALKYLPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND FURTHER DISEASES | JANSSEN SCIENCES IRELAND UC (IE) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239872-A1 | ALKYLPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND FURTHER DISEASES | DPYD, TYMP, PNP | L3MBTL1 2052/4885TLR8 842/4885TLR7 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.